Fesler Andrew, Ju Jingfang
Department of Pathology, Stony Brook University, Stony Brook, NY.
J Pancreatol. 2019 Dec;2(4):147-151. doi: 10.1097/jp9.0000000000000029.
Despite extensive research efforts on diagnosis and treatment, pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease and the third leading cause of cancer-related death in the United States. Resistance to current therapeutic approaches is a major reason for the poor survival of pancreatic patients. In order to overcome this major challenge and improve patient outcomes, we are in desperate need of novel therapeutic approaches. PDAC chemoresistance mechanisms are complex and multifaceted. Novel therapeutics must be equipped to deal with this challenge. microRNAs (miRNAs) have emerged as strong candidates to fill this role due to their multitargeted function. miRNAs have been shown to have important roles in pancreatic cancer resistance. In this review, we summarize the recent advancement in miRNA research related to PDAC therapeutic resistance mechanisms and the potential of miRNAs as therapeutic agents for future clinical management of PDAC.
尽管在胰腺癌的诊断和治疗方面进行了广泛的研究，但胰腺导管腺癌（PDAC）仍然是一种极具破坏性的疾病，是美国癌症相关死亡的第三大主要原因。对当前治疗方法的耐药性是胰腺癌患者生存率低的主要原因。为了克服这一重大挑战并改善患者预后，我们迫切需要新的治疗方法。PDAC的化疗耐药机制复杂且多方面。新型疗法必须有能力应对这一挑战。微小RNA（miRNA）因其多靶点功能而成为填补这一角色的有力候选者。已证明miRNA在胰腺癌耐药中发挥重要作用。在本综述中，我们总结了与PDAC治疗耐药机制相关的miRNA研究的最新进展，以及miRNA作为PDAC未来临床管理治疗剂的潜力。
